Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Stroke

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 37 articles:
HTML format
Text format



Single Articles


    February 2017
  1. ARMSTRONG PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, et al
    Corrigendum to "Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial" [Am Heart J 169/6 (2015) 890-898].
    Am Heart J. 2017;184:157.
    PubMed     Text format    


    April 2016
  2. GOLWALA H, Jackson LR 2nd, Simon DN, Piccini JP, et al
    Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry.
    Am Heart J. 2016;174:29-36.
    PubMed     Text format     Abstract available


    February 2016
  3. EISEN A, Giugliano RP, Ruff CT, Nordio F, et al
    Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myoc
    Am Heart J. 2016;172:144-51.
    PubMed     Text format     Abstract available


  4. DIDIER R, Gaglia MA Jr, Koifman E, Kiramijyan S, et al
    Cerebrovascular accidents after percutaneous coronary interventions from 2002 to 2014: Incidence, outcomes, and associated variables.
    Am Heart J. 2016;172:80-7.
    PubMed     Text format     Abstract available


    January 2016
  5. JONES WS, Patel MR, Tsai TT, Shetterly SM, et al
    Response to Letter to the Editor regarding "Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization".
    Am Heart J. 2016;171:e7.
    PubMed     Text format    


  6. EYUBOGLU M
    Clinical outcomes in patients with lower extremity peripheral artery disease undergoing revascularization.
    Am Heart J. 2016;171:e5.
    PubMed     Text format    


    December 2015
  7. CHANDRASEKHAR J, Mastoris I, Baber U, Sartori S, et al
    Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry.
    Am Heart J. 2015;170:1234-42.
    PubMed     Text format     Abstract available


  8. LEE RJ, Lakkireddy D, Mittal S, Ellis C, et al
    Percutaneous alternative to the Maze procedure for the treatment of persistent or long-standing persistent atrial fibrillation (aMAZE trial): Rationale and design.
    Am Heart J. 2015;170:1184-94.
    PubMed     Text format     Abstract available


  9. AULIN J, Siegbahn A, Hijazi Z, Ezekowitz MD, et al
    Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
    Am Heart J. 2015;170:1151-60.
    PubMed     Text format     Abstract available


  10. MAGNUSON EA, Vilain K, Wang K, Li H, et al
    Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.
    Am Heart J. 2015;170:1140-50.
    PubMed     Text format     Abstract available


    November 2015
  11. MELDUNI RM, Lee HC, Bailey KR, Miller FA Jr, et al
    Real-time physiologic biomarker for prediction of atrial fibrillation recurrence, stroke, and mortality after electrical cardioversion: A prospective observational study.
    Am Heart J. 2015;170:914-22.
    PubMed     Text format     Abstract available


    October 2015
  12. BANSILAL S, Bloomgarden Z, Halperin JL, Hellkamp AS, et al
    Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fi
    Am Heart J. 2015;170:675-682.
    PubMed     Text format     Abstract available


    September 2015
  13. LABAF A, Grzymala-Lubanski B, Sjalander A, Svensson PJ, et al
    Glomerular filtration rate and association to stroke, major bleeding, and death in patients with mechanical heart valve prosthesis.
    Am Heart J. 2015;170:559-65.
    PubMed     Text format     Abstract available


  14. PASTORI D, Pignatelli P, Farcomeni A, Cangemi R, et al
    Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation.
    Am Heart J. 2015;170:490-497.
    PubMed     Text format     Abstract available


    August 2015
  15. JONES WS, Patel MR, Tsai TT, Go AS, et al
    Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization.
    Am Heart J. 2015;170:400-408.
    PubMed     Text format     Abstract available


    July 2015
  16. DAMLUJI AA, Al-Damluji MS, Marzouka GR, Coffey JO, et al
    New-onset versus prior history of atrial fibrillation: Outcomes from the AFFIRM trial.
    Am Heart J. 2015;170:156-163.
    PubMed     Text format     Abstract available


  17. POKORNEY SD, Simon DN, Thomas L, Fonarow GC, et al
    Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
    Am Heart J. 2015;170:141-148.
    PubMed     Text format     Abstract available


  18. CRESSMAN AM, Macdonald EM, Yao Z, Austin PC, et al
    Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study.
    Am Heart J. 2015;170:133-140.
    PubMed     Text format     Abstract available


  19. OKRAINEC K, Bell CM, Hollands S, Booth GL, et al
    Risk of cardiovascular events and mortality among a population-based cohort of immigrants and long-term residents with diabetes: Are all immigrants healthier and if so, for how long?
    Am Heart J. 2015;170:123-32.
    PubMed     Text format     Abstract available


  20. ERDMANN E, Califf R, Gerstein HC, Malmberg K, et al
    Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
    Am Heart J. 2015;170:117-22.
    PubMed     Text format     Abstract available


  21. LIAKOPOULOS OJ, Kuhn EW, Hellmich M, Kuhr K, et al
    Statin Recapture Therapy before Coronary Artery Bypass Grafting Trial: Rationale and study design of a multicenter, randomized, double-blinded controlled clinical trial.
    Am Heart J. 2015;170:46-54.
    PubMed     Text format     Abstract available


  22. XIAN Y, O'Brien EC, Fonarow GC, Olson DM, et al
    Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care.
    Am Heart J. 2015;170:36-45.
    PubMed     Text format     Abstract available


    June 2015
  23. SUGIOKA K, Takagi M, Sakamoto S, Fujita S, et al
    Predictors of silent brain infarction on magnetic resonance imaging in patients with nonvalvular atrial fibrillation: A transesophageal echocardiographic study.
    Am Heart J. 2015;169:783-90.
    PubMed     Text format     Abstract available


  24. WANG Y, Li Z, Xian Y, Zhao X, et al
    Rationale and design of a cluster-randomized multifaceted intervention trial to improve stroke care quality in China: The GOLDEN BRIDGE-Acute Ischemic Stroke.
    Am Heart J. 2015;169:767-774.
    PubMed     Text format     Abstract available


  25. SARICH TC, Seltzer JH, Berkowitz SD, Costin' J, et al
    Novel oral anticoagulants and reversal agents: Considerations for clinical development.
    Am Heart J. 2015;169:751-7.
    PubMed     Text format     Abstract available


    May 2015
  26. LIP GY, Merino J, Ezekowitz M, Ellenbogen K, et al
    A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Am Heart J. 2015;169:597-604.
    PubMed     Text format     Abstract available


    March 2015
  27. MELGAARD L, Gorst-Rasmussen A, Lip GY, Rasmussen LH, et al
    Female sex is associated with a lower risk of stroke in patients with heart failure.
    Am Heart J. 2015;169:396-403.
    PubMed     Text format     Abstract available


  28. LI S, Wu Y, Du X, Li X, et al
    Rational and design of a stepped-wedge cluster randomized trial evaluating quality improvement initiative for reducing cardiovascular events among patients with acute coronary syndromes in resource-constrained hospitals in China.
    Am Heart J. 2015;169:349-55.
    PubMed     Text format     Abstract available


    January 2015
  29. STAFINSKI T, Menon D, Nardelli A, Bakal J, et al
    Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project.
    Am Heart J. 2015;169:122-31.
    PubMed     Text format     Abstract available


  30. WANG Y, Lichtman JH, Dharmarajan K, Masoudi FA, et al
    National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010.
    Am Heart J. 2015;169:78-85.
    PubMed     Text format     Abstract available


  31. NAVAR-BOGGAN AM, Rymer JA, Piccini JP, Shatila W, et al
    Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke.
    Am Heart J. 2015;169:39-44.
    PubMed     Text format     Abstract available


  32. GRANGER CB, Lopes RD, Hanna M, Ansell J, et al
    Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Am Heart J. 2015;169:25-30.
    PubMed     Text format     Abstract available


  33. CAIRNS JA, Weitz JI
    Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
    Am Heart J. 2015;169:1-3.
    PubMed     Text format    


    December 2014
  34. TRICOCI P, Lokhnygina Y, Huang Z, Van de Werf F, et al
    Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial.
    Am Heart J. 2014;168:869-877.
    PubMed     Text format     Abstract available


  35. GUERRA E, Ndrepepa G, Schulz S, Byrne R, et al
    Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention.
    Am Heart J. 2014;168:862-868.
    PubMed     Text format     Abstract available


  36. VALGIMIGLI M
    Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program.
    Am Heart J. 2014;168:838-45.
    PubMed     Text format     Abstract available


  37. VISCOLI CM, Brass LM, Carolei A, Conwit R, et al
    Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
    Am Heart J. 2014;168:823-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stroke is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: